Stock BLCO BAUSCH + LOMB CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bausch + Lomb Corporation Toronto S.E.

Equities

BLCO

CA0717051076

Medical Equipment, Supplies & Distribution

Market Closed - Toronto S.E.
Other stock markets
 15:55:22 2024-06-14 EDT 		5-day change 1st Jan Change
20.69 CAD +1.22% Intraday chart for Bausch + Lomb Corporation -2.04% -8.73%
06-10 Bausch + Lomb Corporation Announces the U.S. Introduction of Bausch + Lomb Infuse for Astigmatism Daily Disposable Contact Lenses CI
06-03 Bausch + Lomb Brief: Launching "Clinically Proven" Nutritional Supplement for Dry Eyes in the United States MT

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 5,429 5,986 5,309 - -
Enterprise Value (EV) 1 7,511 10,217 9,426 9,113 8,789
P/E ratio 776 x -23.1 x -25.5 x -112 x 40.8 x
Yield - - - - -
Capitalization / Revenue 1.44 x 1.44 x 1.14 x 1.07 x 1.02 x
EV / Revenue 1.99 x 2.46 x 2.02 x 1.84 x 1.69 x
EV / EBITDA 10.4 x 13.8 x 10.9 x 9.45 x 8.11 x
EV / FCF 44.2 x -51.6 x 30.4 x 17.8 x 11.3 x
FCF Yield 2.26% -1.94% 3.29% 5.62% 8.83%
Price to Book 0.77 x 0.87 x 0.78 x 0.74 x -
Nbr of stocks (in thousands) 350,001 350,881 351,828 - -
Reference price 2 15.51 17.06 15.09 15.09 15.09
Announcement Date 2/22/23 2/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 3,765 3,768 4,146 4,658 4,944 5,199
EBITDA 1 - 720 738 864.9 964.8 1,084
EBIT 1 - 585 596 647.5 730.6 832.3
Operating Margin - 15.53% 14.38% 13.9% 14.78% 16.01%
Earnings before Tax (EBT) 1 - 73 -166 -170.7 -103.5 157
Net income 1 182 6 -260 -236 -61.57 129.3
Net margin 4.83% 0.16% -6.27% -5.07% -1.25% 2.49%
EPS 2 - 0.0200 -0.7400 -0.5920 -0.1350 0.3700
Free Cash Flow 1 - 170 -198 310 512 776
FCF margin - 4.51% -4.78% 6.66% 10.36% 14.92%
FCF Conversion (EBITDA) - 23.61% - 35.84% 53.07% 71.59%
FCF Conversion (Net income) - 2,833.33% - - - 600.15%
Dividend per Share 2 - - - - - -
Announcement Date 3/31/22 2/22/23 2/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 889 941 942 996 931 1,035 1,007 1,173 1,099 1,168 1,148 1,242 1,155 1,248
EBITDA 1 170 182 187 181 141 179 187 231 180 203.4 218.4 262.5 215.2 239
EBIT 1 140 148 153 144 107 104 152 195 144 150.4 163.1 206.9 153.4 181
Operating Margin 15.75% 15.73% 16.24% 14.46% 11.49% 10.05% 15.09% 16.62% 13.1% 12.88% 14.21% 16.66% 13.28% 14.5%
Earnings before Tax (EBT) 1 29 27 19 -2 -55 -19 -35 -57 -90 -42.5 -34.5 -1.5 - -
Net income 1 20 5 -18 -1 -90 -32 -84 -54 -167 -41.77 -32.7 -0.6 - -
Net margin 2.25% 0.53% -1.91% -0.1% -9.67% -3.09% -8.34% -4.6% -15.2% -3.58% -2.85% -0.05% - -
EPS 2 0.0600 0.0100 -0.0500 - -0.2600 -0.0900 -0.2400 -0.1500 -0.4800 -0.1150 -0.0850 0.005000 -0.0300 -
Dividend per Share 2 - - - - - - - - - - - - - -
Announcement Date 6/8/22 8/4/22 11/2/22 2/22/23 5/3/23 8/2/23 11/1/23 2/21/24 5/1/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt 1 - 2,082 4,231 4,117 3,804 3,480
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) - 2.892 x 5.733 x 4.76 x 3.943 x 3.211 x
Free Cash Flow 1 - 170 -198 310 512 776
ROE (net income / shareholders' equity) - 4.58% 3.72% 3.04% 4.78% 7.08%
ROA (Net income/ Total Assets) - 3.41% 2.1% 1.68% 2.32% 2.91%
Assets 1 - 175.7 -12,388 -14,086 -2,653 4,438
Book Value Per Share 2 - 20.10 19.50 19.40 20.30 -
Cash Flow per Share 2 - 0.9900 -0.0500 0.7500 1.190 -
Capex 1 - 175 181 252 264 277
Capex / Sales - 4.64% 4.37% 5.41% 5.34% 5.33%
Announcement Date 3/31/22 2/22/23 2/21/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Bausch + Lomb Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
15.09 USD
Average target price
18.71 USD
Spread / Average Target
+24.02%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
ABBOTT LABORATORIES Stock Abbott Laboratories
-5.81% 180B
MEDTRONIC PLC Stock Medtronic plc
-1.63% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.14% 67.55B
DEXCOM, INC. Stock DexCom, Inc.
-6.56% 46.11B
CENCORA, INC. Stock Cencora, Inc.
+13.22% 45.79B
HOYA CORPORATION Stock Hoya Corporation
+2.58% 41.61B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+19.93% 31.07B
TERUMO CORPORATION Stock Terumo Corporation
+11.40% 24.77B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-5.36% 24.27B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. BLCO Stock
  4. BLCO Stock
  5. Financials Bausch + Lomb Corporation